Clinical experience with the use of cyclosporin A in psoriasis. Results of a retrospective study

Journal of Dermatological Treatment

Volumn 16, Issue 4, 2005, Pages 238-241

  Ojeda, R ^a   Regaña, M Sánchez ^a   Massana, J ^a   Oliete, R ^a   Umbert, P ^a  

^a HOSPITAL UNIVERSITARI SAGRAT COR   (Spain)

Author keywords

Continuous therapy; Cyclosporin A; Psoriasis

Indexed keywords

CYCLOSPORIN A;

ACNE; ADULT; AGED; ARTICLE; CELLULITIS; CHRONIC DISEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG USE; EPIGASTRIC PAIN; EXPERIENCE; FEMALE; HIRSUTISM; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MYOPATHY; NATURAL KILLER CELL; OUTCOMES RESEARCH; PRIORITY JOURNAL; PSORIASIS; RETROSPECTIVE STUDY; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TREMOR;

ADULT; AGED; CYCLOSPORINE; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PSORIASIS;

EID: 27744475939     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630510011829     Document Type: Article

References (26)

1. Aliaga A, Armero F, Armijo M, Camacho F, Dauden E, Diaz JL, et al. Sandimmun® (ciclosporina A) en psoriasis crónica severa. Resultados del estudio multicéntrico español. Actas Dermosifiliogr. 1994;5:381-5.
2. Ferrándiz C, Hernanz JM, Puig L, Vanaclocha F. Documento de Consenso Español para el uso de Ciclosporina para microemulsión (Sandimmun Neoral®) en Dermatología. Actas Dermosifiliogr. 2000;91:357-64.
3. Economidou J, Barkis J, Demetriou Z, Avgerinou G, Psarra K, Degiannis D, et al. Effects of Cyclosporin A on immune activation markers in patients with active psoriasis. Dermatology. 1999;199:144-8.
4. Armario JC, Fernández JM. Actualización en el tratamiento de la psoriasis (VIII). Act Dermatolog. 2001;4:343-50.
5. Mueller W, Hermann B. Cyclosporin A for psoriasis. N Engl J Med. 1979;301:355.
6. Doutre MS. Ciclosporin. Ann Dermatol Venereol. 2002;129:392-404.
7. Nakayama J, Hori Y, Nakagama H, Ishibashi Y, Horikoshi T, Ozawa A, et al. Comparison of two therapeutic regimens, continuous monotherapy and intermittent therapy, for long-term maintenance of remission of psoriasis with Cyclosporin A. Eur J Dermatol. 1996;6:341-3.
8. Berth-Jones J, Voorhees JJ. Consensus conference on cyclosporin A microemulsion for psoriasis, June 1996. Br J Dermatol. 1996;135:775-7.
9. Lebwohl M, Ellis C, Gottlieb A, Koo J, Kruger G, Linden K, et al. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol. 1998;39:464-75.
10. Mihatsch MJ, Wolff K. Consensus conference on cyclosporin A for psoriasis, February 1992. Br J Dermatol. 1992;126:621-3.
11. Timonen P, Friend D. Efficacy of low-dose cyclosporine A in psoriasis: results of dose findings studies. Br J Dermatol. 1990;122:57-69.
12. Christophers E, Mrowietz V. Cyclosporine in psoriasis: a multicenter dose finding study in severe plaque psoriasis. J Am Acad Dermatol. 1992;26:86-90.
13. Berth-Jones J, Henderson CA, Munro CS, Rogers S, Chalmers R, Boffa MJ, et al. Treatment of psoriasis with intermittent short course cyclosporin (Neoral®). A multicentre study. Br J Dermatol. 1997;136:527-30.
14. Ho VC, Griffiths CE, Albrecht G, Vanaclocha F, León-Dorantes G, Atakan N, et al. Intermittent short courses of cyclosporin (Neoral®) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomised study. Br J Dermatol. 1999;141:283-91.
15. Grossman RM, Thivolet J, Claudy A, Souteyrand P, Guilhou JJ, Thomas P, et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol. 1994;31:68-74.
16. Grossman RM, Chevret S, Abi-Rached J, Blanchet F, Dubertret L. Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol. 1996;132:623-9.
17. Heydendael V, Spuls P, Ten Berge I, Opmeer B, Bos JD, De Rie MA. Cyclosporin trough levels: is monitoring necessary during short-term treatment in psoriasis? A systemic review and clinical data on trough levels. Br J Dermatol. 2002;147:122-9.
18. Markham T, Watson A, Rogers S. Adverse effects with long-term cyclosporin for severe psoriasis. Clin Exp Dermatol. 2002;27:111-14.
19. Ellis CN. Safety issues with cyclosporine. Int J Dermatol. 1997;36(Suppl 1), 7-10.
20. Bennett W. Cyclosporine nephrotoxicity: implications for dermatology. Int J Dermatol. 1997;36(Suppl 1):11-14.
21. Veller C, Gai F. Safety of cyclosporin A in the treatment of dermatological diseases. J Eur Acad Dermatol Venereol. 2003;17:105-7.
22. Zachariae H. Long-term use of cyclosporine in dermatology. Arch Dermatol. 1996;132:692-4.
23. Zachariae H, Kragballe K, Hansen HE, Marcussen N, Olsen S. Renal biopsy findings in long-term cyclosporin treatment of psoriasis. Br J Dermatol. 1997;136:531-5.
24. Arellano F. Risk of cancer with cyclosporine in psoriasis. Int J Dermatol. 1997;36(Suppl 1):15-17.
25. Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume GC, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 years cohort study. J Invest Dermatol. 2003;120:211-16.
26. Weinstein G. Psoriasis therapy after remission: the next step. Int J Dermatol. 1997;36(Suppl 1):37-40.